Skip to content

The effectiveness of vitrecomy co-adjuvant intravitreal dexamethasone implant for proliferative diabetic retinopathy

The effectiveness of vitrecomy co-adjuvant intravitreal dexamethasone implant for proliferative diabetic retinopathy

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072745
Enrollment
Unknown
Registered
2023-06-25
Start date
2023-06-25
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

proliferative diabetic retinopathy

Interventions

Sponsors

Beijing Tongren Eye center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 72 Years

Inclusion criteria

Inclusion criteria: 1. Patients with proliferative diabetic retinopathy with one of the following three conditions in the selected eye: (1) Tractional retinal detachment found by clinical examination, involving the macula or near the macula, meets the surgical indications for vitrectomy; (2) Vitreous hemorrhage occurs repeatedly or does not absorb; (3) Vitreous hemorrhage is accompanied by tractive retinal detachment confirmed by B-ultrasound; 2. Age 18-70 years old; 3. Agree to join the study and follow up on time.

Exclusion criteria

Exclusion criteria: 1. The general condition is too serious to perform vitrectomy; 2. Previously received intravitreal injection for less than 1 month; 3. Previous history of glaucoma; 4. In cases of vitreous hemorrhage, only point-like local vitreoretinal adhesions were found during the operation; 5. The patient cannot complete the follow-up; 6. Past uveitis, retinal vein occlusion and other diseases that may have macular edema; 7. Previous vitrectomy history.

Design outcomes

Primary

MeasureTime frame
Visual acuity;post operative vitreous hemorrhage;

Secondary

MeasureTime frame
macular retinal thickness;retinal attachment;

Countries

China

Contacts

Public ContactLi Jipeng

Beijing Tongren Eye Center

jipeng2004@sina.com+86 139 1099 8208

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026